Before you buy stock in Gilead Sciences, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Gilead ...

The Q4 earnings report for Exact Sciences (NASDAQ: EXAS) was released on Friday, February 13, 2026 at 04:05 PM. Here's what investors need to know about the latest announcement. Exact Sciences missed ...

Forbes contributors publish independent expert analyses and insights. Bruce Japsen writes about healthcare business and policy. Abbott Laboratories $21 billion deal to acquire cancer test maker Exact ...

Family and consumer sciences professionals shape lives daily, support communities and quietly power some of the country’s most essential industries. For years, the value of that work has been clear to ...

Joel Mokyr, Philippe Aghion and Peter Howitt have been awarded the 2025 Nobel Prize in Economics. (Photo by Jonathan Nackstrand / AFP) / ALTERNATIVE CROP (Photo by JONATHAN NACKSTRAND/AFP via Getty ...

Exact Sciences (EXAS) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of breakeven. This compares to a loss of $0.06 per share a year ago. These figures are ...

A colorectal cancer blood test candidate from Exact Sciences fell short in its pivotal study, but the company is still in the hunt to provide an alternative to the liquid biopsy that was first to ...

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) reported Q4 CY2025 results , with sales up 5.2% year on year to $7.93 billion. On the other hand, the company’s full-year revenue guidance of ...